SCHEMBL3577679

SCHEMBL3577679

C[n+]1ccc2oc(-c3ccc(OCc4ccccc4)cc3)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
HSD17B10 Q99714 3/20 0.48
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
RAB9A P51151 2/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 2/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
GPR119 Q8TDV5 4/20 0.48
CHRNB4 P30926 1/20 0.45
CHRNA3 P32297 1/20 0.45
CHRNA7 P36544 1/20 0.45
CHRNA10 Q9GZZ6 1/20 0.45
CHRNA9 Q9UGM1 1/20 0.45
ENPP3 O14638 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666752 0.85 F2 (0.49) MAPTHSD17B10ALDH1A1SMN1; SMN2RAB9A
SCHEMBL10061921 0.79 SMN1; SMN2 (0.67) MAPTHSD17B10ALDH1A1SMN1; SMN2RAB9A
SCHEMBL321374 0.77 HSD17B10 (0.52) MAPTHSD17B10ALDH1A1SMN1; SMN2RAB9A
SCHEMBL12396814 0.75 ESR1 (0.63) MAPTHSD17B10ALDH1A1SMN1; SMN2RAB9A
SCHEMBL15164307 0.74 HDAC6 (0.46) MAPTHSD17B10ALDH1A1SMN1; SMN2RAB9A
SCHEMBL30785576 0.74 SMN1; SMN2 (0.52) MAPTHSD17B10ALDH1A1SMN1; SMN2RAB9A
SCHEMBL2588586 0.74 GPR119 (0.59) MAPTHSD17B10ALDH1A1SMN1; SMN2RAB9A
SCHEMBL28831170 0.74 TLR9 (0.60) RAB9AMEN1KMT2AGPR119NPC1
SCHEMBL29819579 0.74 TLR9 (0.60) RAB9AMEN1KMT2AGPR119NPC1
SCHEMBL26686691 0.73 SMN1; SMN2 (0.60) MAPTHSD17B10ALDH1A1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
EP-2049548-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB Pharma, S.A. (BE) 2009-04-22 EP disclosed
WO-2008012010-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB PHARMA, S.A. (BE) 2008-01-31 WO disclosed
WO-2008012010-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB PHARMA, S.A. (BE) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands HRH3, HRH4, HRH2 MAPT 2867/4885HSD17B10 2678/4885ALDH1A1 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.